-
With relatively few contraindications to use, progestin-only pills might be a possible candidate for over-the-counter (OTC) use in the United States. But what will it take to move progestin-only pills to the drugstore shelves?
-
Reaching young people with an HIV prevention message is important: The Centers for Disease Control and Prevention (CDC) estimates young people ages 13-29 accounted for 39% of all new HIV infections in 2009.
-
The World Health Organization (WHO) has reaffirmed its guidance that women living with HIV or at high risk of HIV infection can safely use all hormonal contraceptives without restriction following a recent review of links between the contraceptives and HIV acquisition.
-
To provide guidance to clinicians on the use of hormone replacement therapy, the authors conducted a systematic review of the randomized, placebo-controlled trials of menopausal hormone therapy published in English since 2002 that assessed primary prevention of chronic conditions.
-
Poly(adenosine diphosphate [adp]-ribose) polymerase (PARP) is an enzyme participating in low-fidelity DNA repair of single strand breaks. Pharmacologic inhibition of PARP has shown to be effective in tumors lacking homologous recombination, such as those harboring silencing mutations of BRCA1 and 2.
-
-
Researchers from duke university and the university of California, San Francisco enrolled 40 patients with symptoms of overactive bladder (OAB), i.e., urgency, frequency, and/or urge incontinence, and 40 patients with no history of OAB symptoms. The women's view of symptoms and treatments were measured with a utility score.
-
The next patient is a 16-year-old young mother who became pregnant at 14 when the condom broke during intercourse and no emergency contraception was used after the method failure.
-
Check your clinic storeroom for stock of the Sandoz oral contraceptive Introvale. The Princeton, NJ-based company issued a voluntary recall in June 2012 for 10 lots of the generic oral contraceptive following a recent report of a packaging flaw.
-
Research presented at the latest Clinical Meeting of the American College of Obstetricians and Gynecologists indicates that women using an oral contraceptive (OC) with a 26/2 dosing regimen had less severe hormone withdrawal-associated symptoms than those using a 21/7 pill.